Journal
CHINESE JOURNAL OF CANCER
Volume 31, Issue 6, Pages 287-294Publisher
SUN YAT SEN UNIV MED SCI WHO
DOI: 10.5732/cjc.011.10376
Keywords
Tumor-infiltrating lymphocytes; immunotherapy; nasopharyngeal carcinoma
Categories
Funding
- National Natural Science Foundation of China [224-30872981]
- Guangdong Province Natural Science Foundation [10151008901000156]
Ask authors/readers for more resources
Establishing Epstein-Barr virus (EBV)-specific cytolytic T lymphocytes (EBV-CTLs) from peripheral blood mononuclear cells (PBMCs) for adoptive immunotherapy has been reported in EBV-associated malignancies including Hodgkin's lymphoma and nasopharyngeal carcinoma (NPC). In the current study, we performed ex vivo expansion of tumor-infiltrating lymphocytes (TILs) obtained from NPC biopsy specimens with a rapid expansion protocol using anti-CD3 monoclonal antibody (OKT3), recombinant human interleukin (IL)-2, and irradiated PBMCs from healthy donors to initiate the growth of TILs. Young TIL cultures comprised of more than 90% of CD3(+) T cells, a variable percentage of CD3(+)CD8(+) and CD3(+) CD4(+) T cells, and less than 10% of CD3-CD16(+) natural killer cells, a similar phenotype of EBV-CTL cultures from PBMCs. Interestingly, TIL cultures secreted high levels of the Th1 cytokines, interferon gamma (IFN gamma) and tumor necrosis factor-alpha (TNF-alpha), and low levels of the Th2 cytokines, IL-4 and IL-10. Moreover, young TILs could recognize autologous EBV-transformed B lymphoblast cell lines, but not autologous EBV-negative blast cells or allogeneic EBV-negative tumor cells. Taken together, these data suggest that ex vivo expansion of TILs from NPC biopsy tissue is an appealing alternative method to establish T cell-based immunotherapy for NPC.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available